2012 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Journal of the American College of Cardiology

Volumn 60, Issue 7, 2012, Pages 645-681

  Jneid, Hani ^a   Anderson, Jeffrey L ^a   Wright, R Scott ^a   Adams, Cynthia D ^a   Bridges, Charles R ^a   Casey, Donald E ^a   Ettinger, Steven M ^a   Fesmire, Francis M ^a   Ganiats, Theodore G ^a   Lincoff, A Michael ^a   Peterson, Eric D ^a   Philippides, George J ^a   Theroux, Pierre ^a   Wenger, Nanette K ^a   Zidar, James Patrick ^a  

^a NONE

Author keywords

AHA Scientific Statements; antiplatelet therapy; focused update; glycoprotein IIb IIIa inhibitors; myocardial infarction; non ST elevation; P2Y12 receptor inhibitor; percutaneous coronary intervention; thienopyridines; unstable angina

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ARTICLE; CARDIOLOGY; EVIDENCE BASED MEDICINE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; STANDARD; UNITED STATES; UNSTABLE ANGINA PECTORIS;

AMERICAN HEART ASSOCIATION; ANGINA, UNSTABLE; ANTICOAGULANTS; CARDIOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; PLATELET AGGREGATION INHIBITORS; UNITED STATES;

EID: 84866368808     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.06.004     Document Type: Article

References (210)

1. ACCF/AHA Task Force on Practice Guidelines. Methodologies and Policies from the ACCF/AHA Task Force on Practice Guidelines. acc.org.2009. Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf. Accessed March 14, 2012.
2. Institute of Medicine. Clinical Practice Guidelines We Can Trust. 2011, The National Academies Press, Washington, DC.
3. Institute of Medicine. Finding What Works in Health Care: Standards for Systematic Reviews. 2011, The National Academies Press, Washington, DC.
4. Anderson, J.L., Adams, C.D., Antman, E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction). J Am Coll Cardiol 50 (2007), e1–e157.
5. Wright, R.S., Anderson, J.L., Adams, C.D., et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 57 (2011), 1920–1959.
6. Wright, R.S., Anderson, J.L., Adams, C.D., et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 57 (2011), e215–e367.
7. Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
8. Eli Lilly and Co. Prasugrel Label. 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm17149 7.htm Accessed May 2, 2012.
9. Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
10. James, S.K., Roe, M.T., Cannon, C.P., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ, 342, 2011, d3527.
11. Mahaffey, K.W., Wojdyla, D.M., Carroll, K., et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124 (2011), 544–554.
12. AstraZeneca. Brilinta REMS Document. NDA 22-433. 2011. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm26396 4.htm Accessed May 2, 2012.
13. Yusuf, S., Zhao, F., Mehta, S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001), 494–502.
14. Connolly, S.J., Pogue, J., Hart, R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360 (2009), 2066–2078.
15. Diener, H.C., Bogousslavsky, J., Brass, L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004), 331–337.
16. Sacco, R.L., Diener, H.C., Yusuf, S., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359 (2008), 1238–1251.
17. James, S.K., Storey, R.F., Khurmi, N., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation, 2012 May 9 [E-pub ahead of print], doi:10.1161/CIRCULATIONAHA.111.082727.
18. Sabatine, M., Prevention of cardiovascular events (e.g., death from heart or vascular disease, heart attack, or stroke) in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin (PEGASUS). http://clinicaltrials.gov/cts/show/NCT01225562, 2012 Accessed May 16, 2012.
19. Verheugt, F.W., Beware of novel antiplatelet therapy in ACS patients with previous stroke. Circulation, 2012 May 9. [Epub ahead of print], doi:10.1161/CIRCULATIONAHA.112.111930.
20. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). fda.gov. 2009. Available at: http://www.fda.gov/cder/drug/early_comm/clopidogrel_bisulfate.htm. Accessed April 6, 2009.
21. Grines, C.L., Bonow, R.O., Casey, D.E. Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115 (2007), 813–818.
22. Mehta, S.R., Yusuf, S., Peters, R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001), 527–533.
23. Ho, P.M., Maddox, T.M., Wang, L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 (2009), 937–944.
24. Lau, W.C., Gurbel, P.A., The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180 (2009), 699–700.
25. Mega, J.L., Close, S.L., Wiviott, S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009), 354–362.
26. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, American Heart Association, Society for Cardiovascular Angiography and Interventions. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning.”. J Am Coll Cardiol 56 (2010), 321–341.
27. Collet, J.P., Hulot, J.S., Pena, A., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373 (2009), 309–317.
28. Giusti, B., Gori, A.M., Marcucci, R., et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 103 (2009), 806–811.
29. Roden, D.M., Stein, C.M., Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 119 (2009), 2127–2130.
30. Sibbing, D., Stegherr, J., Latz, W., et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30 (2009), 916–922.
31. Simon, T., Verstuyft, C., Mary-Krause, M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360 (2009), 363–375.
32. Sofi, F., Giusti, B., Marcucci, R., et al. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 11 (2011), 199–206.
33. Trenk, D., Hochholzer, W., Fromm, M.F., et al. Cytochrome P450 2C19 681G→A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51 (2008), 1925–1934.
34. Mega, J.L., Close, S.L., Wiviott, S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119 (2009), 2553–2560.
35. Varenhorst, C., James, S., Erlinge, D., et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 30 (2009), 1744–1752.
36. Cannon, C.P., Husted, S., Harrington, R.A., et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 50 (2007), 1844–1851.
37. Holmes, M.V., Perel, P., Shah, T., et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306 (2011), 2704–2714.
38. Mehta, S.R., Tanguay, J.F., Eikelboom, J.W., et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, 376, 2010, 1243.
39. Mehta, S.R., Bassand, J.P., Chrolavicius, S., et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363 (2010), 930–942.
40. Bhatt, D.L., Scheiman, J., Abraham, N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 52 (2008), 1502–1517.
41. Juurlink, D.N., Gomes, T., Ko, D.T., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180 (2009), 713–718.
42. O'Donoghue, M.L., Braunwald, E., Antman, E.M., et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374 (2009), 989–997.
43. Deleted in proof.
44. Gilard, M., Arnaud, B., Cornily, J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008), 256–260.
45. Sibbing, D., Morath, T., Stegherr, J., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101 (2009), 714–719.
46. Small, D.S., Farid, N.A., Payne, C.D., et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48 (2008), 475–484.
47. Wiviott, S.D., Trenk, D., Frelinger, A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116 (2007), 2923–2932.
48. Bhatt, D.L., Cryer, B.L., Contant, C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363 (2010), 1909–1917.
49. Abraham, N.S., Hlatky, M.A., Antman, E.M., et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 56 (2010), 2051–2066.
50. Boersma, E., Simoons, M.L., Reperfusion strategies in acute myocardial infarction. Eur Heart J 18 (1997), 1703–1711.
51. Boersma, E., Harrington, R.A., Moliterno, D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359 (2002), 189–198.
52. CAPTURE Study Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349 (1997), 1429–1435.
53. Hamm, C.W., Heeschen, C., Goldmann, B., et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 340 (1999), 1623–1629.
54. Heeschen, C., Hamm, C.W., Goldmann, B., et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban: PRISM Study Investigators: Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 354 (1999), 1757–1762.
55. Lincoff, A.M., Califf, R.M., Moliterno, D.J., et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 341 (1999), 319–327.
56. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 338 (1998), 1488–1497.
57. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: the PURSUIT Trial Investigators: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339 (1998), 436–443.
58. Roffi, M., Chew, D.P., Mukherjee, D., et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 104 (2001), 2767–2771.
59. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994), 956–961.
60. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997), 1689–1696.
61. Cannon, C.P., Weintraub, W.S., Demopoulos, L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001), 1879–1887.
62. Giugliano, R.P., White, J.A., Bode, C., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360 (2009), 2176–2190.
63. Stone, G.W., Bertrand, M.E., Moses, J.W., et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 297 (2007), 591–602.
64. Kastrati, A., Mehilli, J., Neumann, F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006), 1531–1538.
65. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994), 81–106.
66. Baigent, C., Blackwell, L., Collins, R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
67. Cairns, J.A., Gent, M., Singer, J., et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 313 (1985), 1369–1375.
68. Cohen, M., Adams, P.C., Parry, G., et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial: Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 89 (1994), 81–88.
69. Lewis, H.D. Jr, Davis, J.W., Archibald, D.G., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 309 (1983), 396–403.
70. Ridker, P.M., Cushman, M., Stampfer, M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997), 973–979.
71. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336 (1990), 827–830.
72. Theroux, P., Ouimet, H., McCans, J., et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319 (1988), 1105–1111.
73. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996), 1329–1339.
74. Gollapudi, R.R., Teirstein, P.S., Stevenson, D.D., et al. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 292 (2004), 3017–3023.
75. Steinhubl, S.R., Berger, P.B., Mann, J.T. 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002), 2411–2420.
76. Simoons, M.L., Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357 (2001), 1915–1924.
77. Ottervanger, J.P., Armstrong, P., Barnathan, E.S., et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV–Acute Coronary Syndrome) Trial. Circulation 107 (2003), 437–442.
78. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 354 (1999), 708–715.
79. Cuisset, T., Frere, C., Quilici, J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48 (2006), 1339–1345.
80. von Beckerath, N., Taubert, D., Pogatsa-Murray, G., et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112 (2005), 2946–2950.
81. Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58 (2011), e44–e122.
82. Stone, G.W., Ware, J.H., Bertrand, M.E., et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 298 (2007), 2497–2506.
83. Stone, G.W., White, H.D., Ohman, E.M., et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369 (2007), 907–919.
84. Subherwal, S., Bach, R.G., Chen, A.Y., et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 119 (2009), 1873–1882.
85. Yusuf, S., Wittes, J., Friedman, L., Overview of results of randomized clinical trials in heart disease, I: treatments following myocardial infarction. JAMA 260 (1988), 2088–2093.
86. Cohen, M., Demers, C., Gurfinkel, E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337 (1997), 447–452.
87. Antman, E.M., Cohen, M., Radley, D., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 100 (1999), 1602–1608.
88. Antman, E.M., McCabe, C.H., Gurfinkel, E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 100 (1999), 1593–1601.
89. Mehta, S.R., Granger, C.B., Eikelboom, J.W., et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 50 (2007), 1742–1751.
90. Bizzarri, F., Scolletta, S., Tucci, E., et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 122 (2001), 1181–1185.
91. Bybee, K.A., Powell, B.D., Valeti, U., et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation 112:suppl (2005), I286–I292.
92. Dacey, L.J., Munoz, J.J., Johnson, E.R., et al. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 70 (2000), 1986–1990.
93. Goldman, S., Copeland, J., Moritz, T., et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 77 (1988), 1324–1332.
94. Lincoff, A.M., LeNarz, L.A., Despotis, G.J., et al. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials: Improve Long-term Outcome with abciximab GP IIb/IIIa blockade: Evaluation of Platelet IIb/IIIa Inhibition in STENTing. Ann Thorac Surg 70 (2000), 516–526.
95. Mangano, D.T., Aspirin and mortality from coronary bypass surgery. N Engl J Med 347 (2002), 1309–1317.
96. The Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002), 71–86.
97. Dyke, C.M., Bhatia, D., Lorenz, T.J., et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg 70 (2000), 866–871.
98. Clark, S.C., Vitale, N., Zacharias, J., et al. Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery. Ann Thorac Surg 69 (2000), 762–764.
99. Jones, H.U., Muhlestein, J.B., Jones, K.W., et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation 106:suppl I (2002), I19–I22.
100. Kincaid, E.H., Monroe, M.L., Saliba, D.L., et al. Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 76 (2003), 124–128.
101. Mehta, S.R., Yusuf, S., Granger, C.B., et al. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am Heart J, 150, 2005, 1107.
102. Yusuf, S., Mehta, S.R., Chrolavicius, S., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006), 1464–1476.
103. Stone, G.W., Bertrand, M., Colombo, A., et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 148 (2004), 764–775.
104. Stone, G.W., McLaurin, B.T., Cox, D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006), 2203–2216.
105. Plavix (clopidogrel bisulfate) [package insert]. Bristol-Myers Squibb Sanofi-aventis; 2009.
106. Kim, J.H., Newby, L.K., Clare, R.M., et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 156 (2008), 886–892.
107. Patti, G., Colonna, G., Pasceri, V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005), 2099–2106.
108. Montalescot, G., Sideris, G., Meuleman, C., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 (2006), 931–938.
109. Knudtson, M.L., Flintoft, V.F., Roth, D.L., et al. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 15 (1990), 691–697.
110. Roe, M.T., Granger, C.B., Puma, J.A., et al. Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Am J Cardiol 88 (2001), 1403–1406.
111. Mahaffey, K.W., Ferguson, J.J., Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial. Am Heart J 149 (2005), S81–S90.
112. Ferguson, J.J., Califf, R.M., Antman, E.M., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004), 45–54.
113. Mehta, S.R., Granger, C.B., Boden, W.E., et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 360 (2009), 2165–2175.
114. White, H., Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 358 (2001), 1855–1863.
115. Lincoff, A.M., Kleiman, N.S., Kereiakes, D.J., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292 (2004), 696–703.
116. Bhatt, D.L., Fox, K.A., Hacke, W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006), 1706–1717.
117. De Winter, R.J., Windhausen, F., Corne, J.H., et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 353 (2005), 1095–1104.
118. Luchi, R.J., Scott, S.M., Deupree, R.H., Comparison of medical and surgical treatment for unstable angina pectoris: results of a Veterans Administration Cooperative Study. N Engl J Med 316 (1987), 977–984.
119. Peterson, E.D., Shaw, L.J., Califf, R.M., Risk stratification after myocardial infarction. Ann Intern Med 126 (1997), 561–582.
120. Takaro, T., Hultgren, H.N., Lipton, M.J., et al. The VA cooperative randomized study of surgery for coronary arterial occlusive disease II: subgroup with significant left main lesions. Circulation 54:suppl (1976), III107–III117.
121. Bonello, L., Camoin-Jau, L., Armero, S., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 103 (2009), 5–10.
122. Breet, N.J.van Werkum J.W., Bouman, H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303 (2010), 754–762.
123. Marcucci, R., Gori, A.M., Paniccia, R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 119 (2009), 237–242.
124. Matetzky, S., Shenkman, B., Guetta, V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004), 3171–3175.
125. Sofi, F., Marcucci, R., Gori, A.M., et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis. Thromb Haemost 103 (2010), 841–848.
126. Shuldiner, A.R., O'Connell, J.R., Bliden, K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302 (2009), 849–857.
127. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343 (1994), 311–322.
128. Neumann, F.J., Kastrati, A., Pogatsa-Murray, G., et al. Evaluation of prolonged antithrombotic pretreatment (“cooling-off” strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 290 (2003), 1593–1599.
129. Montalescot, G., Cayla, G., Collet, J.P., et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA 302 (2009), 947–954.
130. Gray, W.A., Yadav, J.S., Verta, P., et al. The CAPTURE registry: predictors of outcomes in carotid artery stenting with embolic protection for high surgical risk patients in the early post-approval setting. Catheter Cardiovasc Interv 70 (2007), 1025–1033.
131. Hochman, J.S., Sleeper, L.A., Webb, J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK Investigators: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 341 (1999), 625–634.
132. Damman, P., Hirsch, A., Windhausen, F., et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial: a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 55 (2010), 858–864.
133. Jolly, S.S., Pogue, J., Haladyn, K., et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 30 (2009), 900–907.
134. Steinhubl, S.R., Bhatt, D.L., Brennan, D.M., et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 150 (2009), 379–386.
135. Wyse, D.G., Waldo, A.L., DiMarco, J.P., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002), 1825–1833.
136. Weintraub, W.S., Ba'albaki, H.A., Decision analysis concerning the application of echocardiography to the diagnosis and treatment of mural thrombi after anterior wall acute myocardial infarction. Am J Cardiol 64 (1989), 708–716.
137. Vaitkus, P.T., Barnathan, E.S., Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol 22 (1993), 1004–1009.
138. Sherman, D.G., Dyken, M.L., Fisher, M., et al. Antithrombotic therapy for cerebrovascular disorders. Chest 95 (1989), 140S–155S.
139. Reeder, G.S., Lengyel, M., Tajik, A.J., et al. Mural thrombus in left ventricular aneurysm: incidence, role of angiography, and relation between anticoagulation and embolization. Mayo Clin Proc 56 (1981), 77–81.
140. Lip, G.Y., Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Postgrad Med J 72 (1996), 731–738.
141. Keating, E.C., Gross, S.A., Schlamowitz, R.A., et al. Mural thrombi in myocardial infarctions: prospective evaluation by two-dimensional echocardiography. Am J Med 74 (1983), 989–995.
142. Fuster, V., Ryden, L.E., Asinger, R.W., et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 38 (2001), 1231–1266.
143. Cregler, L.L., Antithrombotic therapy in left ventricular thrombosis and systemic embolism. Am Heart J 123 (1992), 1110–1114.
144. Al-Khadra, A.S., Salem, D.N., Rand, W.M., et al. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 31 (1998), 749–753.
145. Alexander, K.P., Chen, A.Y., Roe, M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005), 3108–3116.
146. Gent, A.E., Brook, C.G., Foley, T.H., et al. Dipyridamole: a controlled trial of its effect in acute myocardial infarction. Br Med J 4 (1968), 366–368.
147. Brouwer, M.A.van den Bergh P.J., Aengevaeren, W.R., et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 106 (2002), 659–665.
148. Fiore, L.D., Ezekowitz, M.D., Brophy, M.T., et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 105 (2002), 557–563.
149. Hurlen, M., Abdelnoor, M., Smith, P., et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347 (2002), 969–974.
150. van Es, R.F., Jonker, J.J., Verheugt, F.W., et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360 (2002), 109–113.
151. Mohr, J.P., Thompson, J.L., Lazar, R.M., et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345 (2001), 1444–1451.
152. Peverill, R.E., Harper, R.W., Smolich, J.J., CARS trial: warfarin and thrombin generation: Coumadin Aspirin Reinfarction Study. Lancet 350 (1997), 1177–1178.
153. Norhammar, A., Malmberg, K., Diderholm, E., et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 43 (2004), 585–591.
154. Chaitman, B.R., Hardison, R.M., Adler, D., et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 120 (2009), 2529–2540.
155. Finfer, S., Chittock, D.R., Su, S.Y., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360 (2009), 1283–1297.
156. Kosiborod, M., Inzucchi, S.E., Goyal, A., et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 301 (2009), 1556–1564.
157. Malmberg, K., Norhammar, A., Wedel, H., et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 99 (1999), 2626–2632.
158. Van den Berghe, G., Wilmer, A., Hermans, G., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 354 (2006), 449–461.
159. Antman, E.M., Anbe, D.T., Armstrong, P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 44 (2004), E1–E211.
160. Kushner, F.G., Hand, M., Smith, S.C. Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54 (2009), 2205–2241.
161. Wiener, R.S., Wiener, D.C., Larson, R.J., Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 300 (2008), 933–944.
162. Hochholzer, W., Trenk, D., Frundi, D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005), 2560–2564.
163. Moghissi, E.S., Korytkowski, M.T., DiNardo, M., et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 32 (2009), 1119–1131.
164. Marfella, R., Di Filippo, C., Portoghese, M., et al. Tight glycemic control reduces heart inflammation and remodeling during acute myocardial infarction in hyperglycemic patients. J Am Coll Cardiol 53 (2009), 1425–1436.
165. Deedwania, P., Kosiborod, M., Barrett, E., et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Anesthesiology 109 (2008), 14–24.
166. Rapezzi, C., Biagini, E., Branzi, A., Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 29 (2008), 277–278.
167. Januzzi, J.L., Cannon, C.P., DiBattiste, P.M., et al. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (the TACTICS-TIMI 18 Trial). Am J Cardiol 90 (2002), 1246–1249.
168. Wright, R.S., Reeder, G.S., Herzog, C.A., et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137 (2002), 563–570.
169. Shlipak, M.G., Heidenreich, P.A., Noguchi, H., et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137 (2002), 555–562.
170. Solomon, R., Werner, C., Mann, D., et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331 (1994), 1416–1420.
171. Erley, C.M., Does hydration prevent radiocontrast-induced acute renal failure?. Nephrol Dial Transplant 14 (1999), 1064–1066.
172. Laskey, W.K., Jenkins, C., Selzer, F., et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 50 (2007), 584–590.
173. Freeman, R.V., O'Donnell, M., Share, D., et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 90 (2002), 1068–1073.
174. Charytan, D.M., Wallentin, L., Lagerqvist, B., et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol 4 (2009), 1032–1043.
175. Szummer, K., Lundman, P., Jacobson, S.H., et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 120 (2009), 851–858.
176. Thomsen, H.S., Morcos, S.K., Erley, C.M., et al. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 43 (2008), 170–178.
177. Solomon, R.J., Natarajan, M.K., Doucet, S., et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 115 (2007), 3189–3196.
178. Rudnick, M.R., Davidson, C., Laskey, W., et al. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 156 (2008), 776–782.
179. Kuhn, M.J., Chen, N., Sahani, D.V., et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol 191 (2008), 151–157.
180. Reed, M., Meier, P., Tamhane, U.U., et al. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. J Am Coll Cardiol Intv 2 (2009), 645–654.
181. Heinrich, M.C., Haberle, L., Muller, V., et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 250 (2009), 68–86.
182. Laskey, W., Aspelin, P., Davidson, C., et al. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. Am Heart J 158 (2009), 822–828.
183. Nikonoff, T., Skau, T., Berglund, J., et al. Effects of femoral arteriography and low osmolar contrast agents on renal function. Acta Radiol 34 (1993), 88–91.
184. Niboshi, A., Nishida, M., Itoi, T., et al. Renal function and cardiac angiography. Indian J Pediatr 73 (2006), 49–53.
185. Hayami, S., Ishigooka, M., Suzuki, Y., et al. Comparison of the nephrotoxicity between ioversol and iohexol. Int Urol Nephrol 28 (1996), 615–619.
186. Campbell, D.R., Flemming, B.K., Mason, W.F., et al. A comparative study of the nephrotoxicity of iohexol, iopamidol and ioxaglate in peripheral angiography. Can Assoc Radiol J 41 (1990), 133–137.
187. Liss, P., Persson, P.B., Hansell, P., et al. Renal failure in 57,925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int 70 (2006), 1811–1817.
188. Maeder, M., Klein, M., Fehr, T., et al. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 44 (2004), 1763–1771.
189. Taylor, A.J., Hotchkiss, D., Morse, R.W., et al. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 114 (1998), 1570–1574.
190. Thomsen, H.S., Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol 181 (2003), 1463–1471.
191. Briguori, C., Airoldi, F., D'Andrea, D., et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115 (2007), 1211–1217.
192. Brown, J.R., Block, C.A., Malenka, D.J., et al. Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. J Am Coll Cardiol Intv 2 (2009), 1116–1124.
193. Masuda, M., Yamada, T., Mine, T., et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 100 (2007), 781–786.
194. Merten, G.J., Burgess, W.P., Gray, L.V., et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291 (2004), 2328–2334.
195. Marenzi, G., Assanelli, E., Marana, I., et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354 (2006), 2773–2782.
196. Thiele, H., Hildebrand, L., Schirdewahn, C., et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 55 (2010), 2201–2209.
197. McCullough, P.A., Adam, A., Becker, C.R., et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 98 (2006), 27K–36K.
198. Coca, S.G., Krumholz, H.M., Garg, A.X., et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296 (2006), 1377–1384.
199. Fox, C.S., Muntner, P., Chen, A.Y., et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 121 (2010), 357–365.
200. American Heart Association. Get With the Guidelines. http://www.americanheart.org/GWTG Accessed March 20, 2012.
201. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367 (2006), 569–578.
202. Bonow, R.O., Masoudi, F.A., Rumsfeld, J.S., et al. ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circulation 118 (2008), 2662–2666.
203. Henry, T.D., Sharkey, S.W., Burke, M.N., et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 116 (2007), 721–728.
204. Jacobs, A.K., Regional systems of care for patients with ST-elevation myocardial infarction: being at the right place at the right time. Circulation. 116 (2007), 689–692.
205. Krumholz, H.M., Anderson, J.L., Bachelder, B.L., et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non–ST-Elevation Myocardial Infarction). J Am Coll Cardiol 52 (2008), 2046–2099.
206. Le May, M.R., So, D.Y., Dionne, R., et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 358 (2008), 231–240.
207. National Cardiovascular Data Registry. Action Registry–GWTG. http://www.ncdr.com. 2009. Available at: http://www.ncdr.com/webncdr/ACTION/Default.aspx. Accessed June 10, 2009.
208. QualityNet.com. Measure Comparison (Inpatient Hospital Quality Measures). http://www.qualitynet.org. 2009. Available at: http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1138900297065. Accessed June 10, 2009.
209. The Joint Commission. Acute Myocardial Infarction Core Measure Set. http://www.jointcommission.org. 2009. Available at: http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/Acute+Myocardial+Infarction+Core+Measure+Set.htm. Accessed June 10, 2009.
210. Ting, H.H., Rihal, C.S., Gersh, B.J., et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 116 (2007), 729–736.